Last reviewed · How we verify
Antibiotic administration
Antibiotic administration is a Antibiotic (class varies by specific agent) Small molecule drug developed by University of California, San Diego. It is currently in Phase 3 development for Bacterial infections (specific indication depends on antibiotic class and formulation under investigation).
Antibiotic administration refers to the delivery of antimicrobial agents to treat bacterial infections by inhibiting bacterial growth or killing bacteria.
Antibiotics are administered to treat various conditions, including Ventilator Associated Pneumonia, Helicobacter Pylori Infection, Urinary Tract Infections, and Diabetic Foot Ulcer, as indicated by ClinicalTrials.gov. The antibiotics used include amoxicillin, tetracycline, and furazolidone, which are classified as small molecules according to ChEMBL.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Antibiotic administration |
|---|---|
| Sponsor | University of California, San Diego |
| Drug class | Antibiotic (class varies by specific agent) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Antibiotics work through various mechanisms depending on the specific agent—such as inhibiting cell wall synthesis, disrupting protein translation, or interfering with DNA replication. The goal is to eliminate pathogenic bacteria while minimizing harm to host cells. Administration routes and dosing are optimized based on the infection site, bacterial species, and patient factors.
Approved indications
- Bacterial infections (specific indication depends on antibiotic class and formulation under investigation)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, vomiting)
- Allergic reaction
- Photosensitivity (with certain classes)
- Hepatotoxicity
- Nephrotoxicity
Key clinical trials
- Learning Process of Fourth Year Medical Students During a Doctor-patient Relationship Training
- Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children (NA)
- Comparison of Oral Antibiotics For Bone Infections of the Leg and Foot (PHASE4)
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
- Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
- A Study of Doxycycline to Treat Chlamydial Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antibiotic administration CI brief — competitive landscape report
- Antibiotic administration updates RSS · CI watch RSS
- University of California, San Diego portfolio CI
Frequently asked questions about Antibiotic administration
What is Antibiotic administration?
How does Antibiotic administration work?
What is Antibiotic administration used for?
Who makes Antibiotic administration?
What drug class is Antibiotic administration in?
What development phase is Antibiotic administration in?
What are the side effects of Antibiotic administration?
Related
- Drug class: All Antibiotic (class varies by specific agent) drugs
- Manufacturer: University of California, San Diego — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial infections (specific indication depends on antibiotic class and formulation under investigation)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing